The stock in focus - Neumora Therapeutics Inc. (NMRA) is a clinical-stage biopharmaceutical company that engages in developing treatments for brain, neuropsychiatric, and neurodegenerative diseases in the U.S.
Its lead candidate, Navacaprant (NMRA-140), is a once-daily oral kappa opioid receptor antagonist currently in Phase 3 trials for major depressive disorder. The company is also advancing NMRA-511, now in Phase 1 trials for agitation associated with dementia due to Alzheimer's disease.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.